Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026
Personalis will present four NeXT Personal ctDNA datasets at the ESMO Congress 2026, October 23-27 in Madrid, including two oral presentations. The late-breaking oral covers updated overall survival and ctDNA outcomes from the C-POST Phase 3 trial of adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma, and a Rapid Oral will show first pre-interim data from the prospective B-STRONGER-1 study of ultrasensitive MRD detection in early-stage triple-negative breast cancer.
Key figures
- Drug Name
- NeXT Personal
- Phase Of Trial
- Phase 3 (C-POST); B-STRONGER-1 pre-interim
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.